CAR-T, cancer cell

New CAR-T therapy achieved complete remission in 70% of aggressive cancer patients
CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with remission rates reaching as high as 90%. This therapy modifies a patient’s T cells to recognize and destroy cancer cells.
New CAR-T cell therapy shows promise for hard-to-treat cancers
Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder for prior CAR-T therapies to detect and fight.
CAR T-Cell Therapy Cuts Costs, Reduces Treatment in Mantle Cell Lymphoma
In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.
‘Complete eradication’ of B cells drives remission after autoimmune CAR T-cell therapy
A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment, according to a speaker.
Science for all | What is CAR T cell therapy
Scientists may have unlocked a new milestone in cancer treatment. An individual who received CAR T-cell therapy has been in remission for 18 years without requiring any other treatments, researchers reported in Nature Medicine on February 17.
New CAR-T cell therapy 'ALA-CART' shows promise for hard-to-treat cancers
Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells,
US researchers develop next-gen CAR-T therapy to kill hard-to-treat cancers
CART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of CAR-T cells
Technology Networks4d
Overcoming CAR T-Cell Therapy Limitations
In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...
Supercharged T-Cells Hunt Down the Hardest-to-Treat Cancers
Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...
What Vanderbilt-Ingram Cancer Center's 'sci-fi' therapy means for this grateful TN dad
This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.
Healio4d
‘There is a whole other world out there’: Beyond CAR-T therapies for autoimmune diseases
Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...
Physician's Weekly3d
Late Adverse Events After CAR T-Cell Therapy in Aggressive B-Cell Lymphoma
The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...
Protheragen Unveils Revolutionary EndureCAR-T™ Cell Therapy Platform
Protheragen is an advanced CAR-T cell therapy service provider. With its extensive experience in cell therapy development and ...